Pharmaceutical Executive-11-01-2010

New CER tools grant payers the evidence they need to control drug costs

Once silent, an emerging market raises its voice

Harvard professor Daniel Carpenter offers a piercing analysis of the FDA and sheds light on its biggest challenges

With all the money and momentum focused on medicines in emerging markets, it may be time to take a closer look at business opportunities in this more familiar neighbor to the East

There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?

The FDA process itself is looking more like the unsavory 'sausage factory' associated with drafting partisan legislation

Pharm Exec sits down with an expert on regional marketing to ascertain what it takes to drive strong brand results

A timeline of some of the landmark legislation, court decisions, and drug scandals that helped forge the FDA